Some of our cells, with age or after damage, stop dividing entirely but never die off either. Science calls this "cellular senescence"; in plain language, people call them "zombie cells" — they no longer do their job, but they don't get cleared away, so they just sit there affecting their surroundings. These cells secrete a cocktail called SASP (senescence-associated secretory phenotype) — a mix of inflammatory signals, enzymes and growth factors that can gradually push neighboring healthy cells toward senescence as well. This mechanism is a major source of the chronic, low-grade inflammation we describe in our inflammaging article.
Senolytics is the general name for compounds designed to selectively kill off these zombie cells. The logic is simple: if the buildup of senescent cells accelerates aging, clearing them out might slow aging down or delay age-related disease. Two approaches have drawn the most research over the past decade: plant flavonoids (fisetin, quercetin) and a combination of the prescription cancer drug dasatinib with quercetin — usually shortened to D+Q.
In 2018, researchers from Scripps, Mayo Clinic and the University of Minnesota screened 10 different flavonoids for senolytic activity in cell culture. Fisetin — a compound naturally found in strawberries, apples and onions — came out clearly on top, outperforming even quercetin. The researchers then gave fisetin to 85-week-old mice (roughly equivalent to a human in their mid-70s), late in life. The result: tissue balance improved, age-related pathology decreased, and both median and maximum lifespan were extended. The authors described it as the first senolytic shown to extend both healthspan and lifespan, even when started late in life.
One notable detail: fisetin's effect didn't show up uniformly across all cells, only in specific tissue and cell types — consistent with what researchers describe as a "hit-and-run" mechanism. This strong mouse data was the main driver behind moving fisetin into human trials.
The first study to test senolytics in humans was published in 2019. Researchers gave 14 people diagnosed with idiopathic pulmonary fibrosis (a progressive lung disease) an intermittent combination of dasatinib (100 mg/day) and quercetin (1,250 mg/day), three days a week for three weeks. The trial was open-label, meaning there was no placebo comparison — an important limitation to keep in mind.
Every participant completed treatment, 13 of 14 finished all planned assessments, and one serious adverse event was reported. Physical function measures improved in a statistically significant way: 6-minute walk distance rose by an average of 21.5 meters, with gait speed and chair-stand time also improving. Lung function tests and blood values, on the other hand, showed no meaningful change. James Kirkland, one of the study's senior authors, specifically noted that these results only justify larger, controlled trials, and that patients should not be using these drugs outside of research.
A phase 2 randomized controlled trial published in Nature Medicine in 2024, led by Joshua Farr and Sundeep Khosla at Mayo Clinic, tested intermittent D+Q therapy on bone metabolism in 60 postmenopausal women. Over the 20-week trial, the primary endpoint — a bone resorption marker called CTx — showed no overall difference between the treatment and placebo groups. The bone formation marker P1NP rose in the treatment group at weeks 2 and 4, but that difference disappeared by week 20.
The interesting part showed up in a subgroup analysis: in women with a high senescent-cell burden, D+Q reduced bone resorption, increased bone formation, and produced a measurable increase in radius bone density at 20 weeks. In other words, the treatment didn't seem to work uniformly — it appeared to benefit people with a particular biological profile. No serious adverse events were reported. When announcing the finding, the researchers explicitly warned against the indiscriminate, unsupervised use of senolytic supplements like quercetin.
The SToMP-AD trial, published in Nature Medicine in 2023, gave just 5 people with mild symptomatic Alzheimer's disease D+Q for 12 weeks, on a 2-days-on, 14-days-off schedule. The goal wasn't efficacy — it was safety and feasibility. Both drugs were detectable in the blood of all participants, and dasatinib was found in the cerebrospinal fluid of 4 of the 5, confirming that it crosses the blood-brain barrier as intended. Treatment was well tolerated, with no early discontinuations. But with a sample this small, looking for statistically significant changes in cognitive tests or Alzheimer's biomarkers never really made sense in the first place; the researchers described their findings as "mechanistic hints that need confirmation in larger, placebo-controlled studies." Wake Forest University is now running a larger phase 2 trial on the same question.
It's worth drawing a clear line here. In every human study above, quercetin was given together with dasatinib — a prescription leukemia drug — under a research protocol. No study has shown that fisetin or quercetin alone, bought over the counter or online as a supplement, extends human lifespan or delays disease. The strong fisetin effect seen in mice hasn't yet been confirmed the same way in people.
Dasatinib is a serious drug: it can carry real risks like bone marrow suppression, fluid retention and bleeding, which is why researchers consistently repeat the same warning — this combination should not be used outside medical supervision and a research protocol. Fisetin and quercetin supplements being sold over the counter doesn't mean their effectiveness has been proven; it just means they fall into a different safety category than we might assume. For anyone following this space, the honest summary is that it's an active, unresolved area of research.
Senolytics are compounds that aim to selectively kill off "zombie" (senescent) cells — cells that have stopped dividing but don't die. These cells accumulate in tissue with age and secrete an inflammatory mix called SASP, which can push nearby healthy cells toward senescence too. Plant flavonoids like fisetin and quercetin, and the prescription drug combination dasatinib plus quercetin (D+Q), are the most studied senolytics.
Human studies to date offer no evidence that fisetin or quercetin alone, at supplement doses, extends lifespan. The positive human results come from quercetin used together with prescription dasatinib, under research supervision. Mayo Clinic researchers explicitly warned against the indiscriminate, unsupervised use of senolytic supplements like quercetin.
No. Dasatinib is a prescription chemotherapy drug used to treat leukemia and can carry serious side effects. Human trials so far have involved small groups of 5 to 60 people, under close medical supervision and within a research protocol. The researchers themselves specifically emphasize that these drugs should not be used outside of research, without a doctor's supervision.
"The mouse data for senolytics is genuinely strong. The human data is still small, short-term, and mostly testing safety, not effectiveness. It matters not to confuse the two."
— Vivelong Longevity Science Team